Empagliflozin/linagliptin

Empagliflozin/linagliptin
Combination of
Empagliflozin SGLT2 inhibitor
Linagliptin DPP-4 inhibitor
Clinical data
Routes of
administration		 Oral
Legal status
Legal status
  • ℞ (Prescription only)
  (verify)

Empagliflozin/linagliptin is a drug combination used for the treatment of type II diabetes. It is a combination of empagliflozin and linagliptin. The combination preparation was developed and is marketed by Boehringer Ingelheim and Eli Lilly under the trade name Glyxambi. Glyxambi was approved for use by the FDA in 2015.[1][2]

References

  1. ↑ Swiatek, Jeff (2 February 2015). "2-in-1 diabetes drug from Eli Lilly and partner OK'd". The Indianapolis Star. Retrieved 3 February 2015.
  2. ↑ Penumudi, Amrutha (2 February 2015). "FDA approves Boehringer-Lilly drug for type-2 diabetes patients". Reuters. Retrieved 3 February 2015.
This article is issued from Wikipedia - version of the 2/3/2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.